Hims & Hers Stock Slips Despite Q4 Earnings Beat, Margins Contract

Core Insights - Hims & Hers Health, Inc. reported a fourth-quarter 2025 EPS of 7 cents, down from 11 cents year-over-year, but exceeding the Zacks Consensus Estimate of 2 cents [1] - Full-year EPS was 51 cents, reflecting a 3.8% decrease from the previous year, yet surpassing the Zacks Consensus Estimate by 6.3% [1] Revenue Performance - Fourth-quarter revenues reached $617.8 million, a 28.4% increase year-over-year, but slightly below the Zacks Consensus Estimate by 0.2% [2] - Full-year revenues totaled $2.35 billion, marking a 58.9% improvement from the prior year and aligning with the Zacks Consensus Estimate [2] Geographical Results - U.S. revenues in Q4 2025 improved by 16.8% year-over-year to $554.1 million, while revenues from the Rest of the World surged to $63.7 million from $6.9 million in the previous year [3] Segment Analysis - Online Revenues for the quarter were $609.1 million, reflecting a 29.4% year-over-year increase, with total subscribers reaching 2.5 million, up 12.7% [4] - Wholesale Revenues were reported at $8.7 million, down 16.1% year-over-year [6] Margin and Expense Analysis - Gross profit increased by 20.3% year-over-year to $444.4 million, but gross margin contracted by 487 basis points to 71.9% [7] - Operating expenses rose 24% year-over-year to $435.2 million, leading to an operating profit of $9.2 million, a 50.6% decline from the previous year [8] Financial Position - Hims & Hers ended 2025 with cash and cash equivalents of $577.5 million, up from $300.3 million at the end of 2024 [9] - Cumulative net cash from operating activities was $300 million, compared to $251.1 million a year prior [9] Future Outlook - For Q1 2026, the company projects revenues between $600 million and $625 million, indicating a year-over-year growth of 2%-7% [10] - Full-year revenue guidance for 2026 is set between $2.7 billion and $2.9 billion, representing a growth of 15%-24% from 2025 levels [11] Strategic Developments - Hims & Hers has entered an agreement to acquire Eucalyptus, expanding its reach in consumer healthcare across multiple countries [13] - Recent product launches, including a cancer screening blood test and health assessment tools, are expected to enhance subscriber engagement and revenue [14] Market Reaction - Shares of Hims & Hers fell nearly 6.3% in pre-market trading following the earnings report [2] - The company currently holds a Zacks Rank of 4 (Sell) [16]